To the Editor The chikungunya virus–like particle (CHIKV VLP) vaccine described in a recent article by Dr Chen and colleagues1 is one of several chikungunya vaccines that have completed either phase 1 or preclinical phases.2 The phase 2 randomized clinical trial reported focuses on pertinent clinical questions of safety and tolerability of the vaccine in a chikungunya-endemic area. The trial enrolled healthy adults aged 18 through 60 years who had tested negative for chikungunya virus IgM/IgG and randomized them to receive 20 μg of the vaccine or a placebo. Both safety and tolerability were demonstrated.
Jaiswal N, Singh S, Singh M. Chikungunya Virus–Like Particle Vaccine. JAMA. 2020;324(10):1008. doi:10.1001/jama.2020.11845
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: